Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol.

Haematologica
Virginie GandemerFRALLE Group

Abstract

The prognosis of patients with relapses of ETV6/RUNX1-positive acute lymphoblastic leukemia remains to be evaluated, particularly with regards to the frequency of late relapses. We performed a long-term, follow-up retrospective study to address the outcome of patients with ETV6/RUNX1-positive leukemia relapses. Among the 713 children tested for ETV6/RUNX1 enrolled into the FRALLE 93 protocol, 43 ETV6/RUNX1-positive patients relapsed (19.4%). Most were initially stratified in the low or intermediate risk groups. The median follow-up after relapse was 54.2 months. All but three received second-line salvage therapy and 16 underwent allogeneic transplantation. ETV6/RUNX1 had a strong effect on overall survival after relapse (3-year survival= 64.7% for positive cases versus 46.5% for negative cases) (P=0.007). The 5-year cumulative incidence of relapse was 19.4% and testes were more frequently involved in ETV6/RUNX1-positive relapses (P=0.04). In 81.4% of cases the relapses were late, early combined or isolated extramedullary relapses. The 5-year survival rate of patients with ETV6-RUNX1-positive acute lymphoblastic leukemia relapses reached 80.8% when the relapse occurred after 36 months (versus 31.2% when the relapse occurred earl...Continue Reading

References

May 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·A M FordM Greaves
Nov 7, 1999·Lancet·J L WiemelsM F Greaves
Nov 18, 2003·British Journal of Haematology·Judith M ChessellsIan M Hann
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jan ZunaMel Greaves
Dec 15, 2005·British Journal of Haematology·Paul S Gaynon
Feb 5, 2008·British Journal of Haematology·Erik ForestierUNKNOWN NOPHO Leukaemia Cytogenetic Study Group (NLCSG)
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth A RaetzWilliam L Carroll
Sep 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Carine DomenechYves Bertrand
Nov 29, 2008·Science·Charles G MullighanJames R Downing
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter BaderUNKNOWN ALL-REZ BFM Study Group
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gesche TallenArend von Stackelberg

❮ Previous
Next ❯

Citations

May 4, 2013·The Lancet Oncology·Deepa Bhojwani, Ching-Hon Pui
Jul 24, 2013·Oncology Reports·Ioannis PanagopoulosSverre Heim
Dec 2, 2014·Pediatric Clinics of North America·Stacy L Cooper, Patrick A Brown
May 1, 2016·Annals of Diagnostic Pathology·Yi ZhouCarlos E Bueso-Ramos
Nov 5, 2014·Cytometry. Part B, Clinical Cytometry·Chantal FossatUNKNOWN French Multicenter Study Groups for Pediatric and Adult ALL
Jun 19, 2015·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Ansar HakeemA R Lone
Aug 11, 2016·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jae Wook LeeHack-Ki Kim
Jan 29, 2019·International Journal of Hematology·Ikuya UsamiUNKNOWN Japan Association of Childhood Leukemia Study Group (JACLS)
Aug 21, 2019·Molecular Genetics & Genomic Medicine·Congcong SunXiaofan Zhu
Nov 20, 2016·Clinical Journal of Oncology Nursing·Stephanie JacobsonJulie Eggert
Apr 4, 2021·International Journal of Molecular Sciences·Princess D RodriguezSeth Frietze

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.